TECTA

From WikiMD's WELLNESSPEDIA

TECTA is a gene that encodes the protein alpha-tectorin, which is a major component of the tectorial membrane in the inner ear. Mutations in this gene can lead to autosomal dominant non-syndromic sensorineural types of hearing impairment, such as DFNA8 and DFNA12, or autosomal recessive type of hearing impairment, DFNB21.

Function[edit]

The TECTA gene provides instructions for making a protein called alpha-tectorin. This protein is a crucial part of the tectorial membrane, a structure in the inner ear that plays a critical role in hearing. The tectorial membrane responds to sound waves by moving back and forth, which stimulates sensory cells to send signals to the brain that are interpreted as sound.

Clinical significance[edit]

Mutations in the TECTA gene can cause autosomal dominant non-syndromic sensorineural hearing loss, which is a type of hearing loss that occurs when the inner ear or nerve pathways from the inner ear to the brain are damaged. This type of hearing loss is typically not associated with other signs and symptoms.

There are three types of hearing loss associated with TECTA gene mutations: DFNA8, DFNA12, and DFNB21. DFNA8 and DFNA12 are inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. DFNB21 is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations.

See also[edit]

References[edit]


External links[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.